GSTM1 and atrial fibrillation: We compared the incidence of all GI bleeding that required hospitalization and cessation of the active drug, as opposed to ROCKET AF trial which separated major GI bleeding (which was associated with dropping Hb by 2 g/dL or requiring transfusion of 2 units of blood) from nonmajor bleeding.